证券代码：688012 证券简称：中微公司 公告编号：2025-023 第三个归属期归属结果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为755,028 股。 本次股票上市流通总数为755,028股。 本次股票上市流通日期为2025 年 4 月 29 日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分公 司有关业务规则的规定，中微半导体设备（上海）股份有限公司于 2025 年 4 月 24 日收到中国证券登记结算有限责任公司上海分公司出具的《证券变更登记证明》， 公司于 2025 年 4 月 23 日完成了 2022 年限制性股票激励计划第三个归属期的股份 登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 中微半导体设备（上海）股份有限公司 关于 2022 年限制性股票激励计划 （1）2022 年 3 月 9 日，公司召开第二届董事会第三次会议，会议审议通过了 《关于公司< ...

Financial Performance - The company's revenue for Q1 2025 reached CNY 2.173 billion, representing a year-on-year growth of 35.40%[4] - Net profit attributable to shareholders was CNY 313 million, an increase of 25.67% compared to the same period last year[7] - Operating profit for Q1 2025 was ¥294,467,825.63, compared to ¥254,409,633.95 in Q1 2024, reflecting a growth of 15.7%[22] - Net profit for Q1 2025 was ¥308,245,968.10, up from ¥248,855,112.06 in Q1 2024, marking a 23.9% increase[22] - The total comprehensive income for Q1 2025 was ¥316,757,327.16, compared to ¥246,253,314.81 in Q1 2024, showing a growth of 28.5%[23] - The company reported a basic earnings per share of ¥0.50 for Q1 2025, compared to ¥0.40 in Q1 2024, indicating improved profitability per share[23] Research and Development - R&D investment totaled CNY 687 million, up 90.53% year-on-year, accounting for 31.60% of revenue, significantly higher than the average of 10%-15% for companies listed on the Sci-Tech Innovation Board[3] - The company successfully launched six new thin-film devices for advanced storage and logic devices, achieving international leading performance[2] - The company aims to accelerate the development of competitive new devices, reducing the typical development time from three to five years to two years or less[3] - Research and development expenses in Q1 2025 amounted to ¥464,353,795.33, significantly higher than ¥214,189,022.44 in Q1 2024, indicating a focus on innovation[21] Cash Flow and Liquidity - Cash flow from operating activities was CNY 377 million, a significant recovery from a negative cash flow of CNY 586 million in the previous year[4] - Cash flow from operating activities for Q1 2025 was ¥2,925,165,528.78, compared to ¥1,743,700,132.21 in Q1 2024, representing a 67.8% increase[25] - The net cash flow from operating activities was 376,808,177.47, compared to a negative cash flow of 586,440,411.60 in the previous period, indicating a significant improvement[26] - The total cash and cash equivalents at the end of the period amounted to 5,936,043,895.92, an increase from 5,207,023,770.05 in the prior period[27] Assets and Liabilities - Total assets as of March 31, 2025, amounted to CNY 27,118,584,850.11, an increase from CNY 26,217,544,719.07 as of December 31, 2024, reflecting a growth of approximately 3.43%[17] - Total liabilities as of the end of the reporting period were ¥6,980,583,129.65, up from ¥6,482,002,827.11 in the previous period[20] - Total equity attributable to shareholders increased to ¥20,144,123,516.91 from ¥19,736,912,284.36, reflecting a growth of 2.1%[20] Shareholder Information - The company reported a total of 45,640 common shareholders at the end of the reporting period[13] - The largest shareholder, Shanghai Chuangye Investment Co., Ltd., holds 93,483,533 shares, representing 15.02% of total shares[13] - The second-largest shareholder, Xunxin (Shanghai) Investment Co., Ltd., owns 80,996,822 shares, accounting for 13.01%[13] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[16] Investment Activities - The total cash inflow from investment activities was 1,698,861,184.27, down from 4,817,822,502.46 in the prior period, reflecting a decrease of approximately 64.7%[26] - The cash outflow from investment activities totaled 1,779,693,358.10, compared to 2,367,634,196.95 previously, showing a reduction of about 25%[26] - The net cash flow from investment activities was -80,832,173.83, contrasting with a positive cash flow of 2,450,188,305.51 in the last period, indicating a significant decline[26] Employee Compensation and Taxes - The cash outflow for employee compensation was 563,717,826.76, up from 395,203,021.59, indicating an increase of approximately 42.5%[26] - The cash paid for taxes was 258,714,301.73, compared to 161,208,019.68 previously, reflecting an increase of about 60.5%[26]

一、并购 1、纳微科技：投资1576.92万元取得纳信科技51.25%股权。 5、三联锻造：设立机器人及航空部件研究院分公司。 6、金杨股份：投资不超9000万美元建设马来西亚锂电池精密结构件项目。 7、中毅达：公司生产产能保持稳定，近期无新建计划。 二、回购、增持 1、古越龙山：拟2亿元-3亿元回购。 2、凯撒旅业：控股股东拟0.7亿元-1.1亿元增持。 三、对外投资，日常经营 1、星网宇达：公司与吉林省仿生机器人创新中心签署战略合作协议。 2、中国平安：计划发行不超过500亿元人民币的境内债券融资工具。 3、纽威数控：拟投资8.5亿元建设五期高端智能数控装备项目。 4、元利科技：拟投资7.6亿元建设年产25000吨受阻胺类光稳定剂项目。 1、恒玄科技：2024年净利润4.60亿，同比增长272% 拟每10股派发12元并转增4股。 四、业绩变动 2、中微公司：一季度净利润3.13亿元 同比增长25.67%；公司针对先进逻辑和存储器件制造中关键刻蚀 工艺的高端产品新增付运量显著提升，六种薄膜设备已顺利进入市场。 3、惠而浦：一季度净利润1.16亿元，同比增长1029%；主要系外销订单增加。 4、甘李药业：一季 ...

Core Viewpoint - The company reported a significant increase in revenue and net profit for the first quarter of 2025, driven by innovation in advanced process technology and increased shipment of high-end products [1] Financial Performance - The company's revenue for Q1 2025 reached 2.173 billion yuan, representing a year-on-year growth of 35.40% [1] - The net profit attributable to shareholders was 313 million yuan, showing a year-on-year increase of 25.67% [1] Innovation and Product Development - The company has made continuous innovations in advanced process technology, particularly in critical etching processes for advanced logic and memory device manufacturing [1] - The shipment volume of six types of thin film equipment has significantly increased, successfully entering the market [1] Research and Development - The company has increased its R&D investment to approximately 687 million yuan, which is a year-on-year growth of about 90.53% [1]

Core Insights - The latest net value of Wanjiay Economic New Momentum Mixed C Fund (005312) is 1.6754 yuan, reflecting a decrease of 0.66% [1] - The fund has shown a return of 3.35% over the past month, ranking 200 out of 4491 in its category; a return of 32.05% over the past three months, ranking 29 out of 4444; and a year-to-date return of 33.98%, ranking 34 out of 4418 [1] Fund Holdings - The top ten stock holdings of Wanjiay Economic New Momentum Mixed C Fund account for a total of 75.95%, with the following allocations: - Ruixin Microelectronics (9.12%) - BeiGene-U (8.80%) - Deepin Technology (8.64%) - Innovent Biologics-U (7.88%) - Cambricon Technologies-U (7.65%) - iFlytek (7.51%) - Sierpo (7.46%) - Sanan Optoelectronics (6.89%) - BGI Genomics (6.18%) - Zhongwei Company (5.82%) [1] Fund Overview - Wanjiay Economic New Momentum Mixed C Fund was established on February 7, 2018, and as of March 31, 2025, it has a total scale of 1.223 billion yuan [1] - The fund manager is Huang Xingliang, who has extensive experience in the investment management industry [2]

机构观点显示，高盛维持亚太股市 "增持" 评级，建议超配半导体（SK 海力士、北方华创）和消费电子（立讯精密）；摩根士丹利下调澳大利亚股市评级 至 "中性"，建议转向金融（CBA）和医疗（CSL）板块；中信证券提示 A 股短期关注 3300 点突破力度，若放量站稳可加仓科技股，反之需减仓防御，等 待回调至 3250 点支撑位。 总体来看，今日亚太股市在美股反弹和中国经济数据支撑下普涨，但量能不足制约 A 股突破空间。投资者需关注美联储政策预期、地缘政治风险及市场 估值压力，短期可把握科技与消费双主线轮动机会，中长期布局高景气赛道（AI、半导体、智能汽车）及防御性资产（黄金、高股息）。关键数据与事 件方面，需关注 4 月 PMI 数据（4 月 30 日公布）、5 年期 LPR 调整（5 月 20 日）、美联储 5 月 FOMC 会议（5 月 14-15 日）及美国 4 月非农就业报告 （5 月 3 日）。 2025 年 4 月 23 日亚太股市延续震荡上行态势，日经 225 指数涨 1.72% 报 34808.8 点，韩国 KOSPI 指数涨 1.47% 报 2523.3 点，澳大利亚 ASX200 指数涨 1 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 226.67 CNY [3][5][9] Core Insights - The company has shown continuous high revenue growth, with a projected revenue of 90.7 billion CNY in 2024, representing a 45% year-on-year increase [8] - The company significantly increased its R&D investment to approximately 2.45 billion CNY in 2024, a 94% increase compared to the previous year, driven by the rising demand for new equipment [8] - The company's contract liabilities surged by 235% to approximately 2.59 billion CNY by the end of 2024, indicating strong order expectations [8] Financial Performance Summary - Revenue (in million CNY) is projected to grow from 6,264 in 2023 to 20,009 in 2027, with year-on-year growth rates of 32%, 45%, 33%, 30%, and 28% respectively [4] - The net profit attributable to the parent company is expected to rise from 1,786 million CNY in 2023 to 4,463 million CNY in 2027, with growth rates of 53%, -10%, 51%, 38%, and 33% [4] - The gross margin is projected to decline from 45.8% in 2023 to 41.1% in 2024, primarily due to structural changes in customer composition and discounts offered [8] Equipment Sales and Market Position - The company experienced significant growth in etching equipment sales, with over 1,200 reaction chambers shipped in 2024, marking a historical high [8] - The company's new deposition equipment, including LPCVD and ALD, has successfully entered the market, with over 150 reaction chambers shipped in 2024 [8] - The ICP etching equipment has been installed in over 1,025 reaction chambers across more than 50 customer production lines, achieving an average annual growth rate exceeding 100% over the past four years [8]

Group 1 - The Shanghai Stock Exchange Science and Technology Innovation Board Composite Index decreased by 0.11% as of April 22, 2025, with mixed performance among constituent stocks [1] - The leading gainers included Shijia Photon up 13.09%, Baili Tianheng up 11.41%, and Shanwaishan up 10.80%, while the biggest losers were Kangpeng Technology down 8.62%, Zhiyuan Huitong down 7.69%, and Suochen Technology down 7.25% [1] - The Huaxia Science and Technology Innovation Index ETF (589000) fell by 0.32%, with the latest price at 0.94 yuan [1] Group 2 - The Huaxia Science and Technology Innovation Index ETF reached a new high in scale at 2.473 billion yuan, ranking first among comparable funds [1] - The ETF exhibited a turnover rate of 4.55% during the trading session, with a transaction volume of 113 million yuan [1] - Over the past week, the ETF averaged a daily transaction volume of 114 million yuan, also ranking first among comparable funds [1] Group 3 - The Huaxia Science and Technology Innovation Index ETF experienced continuous net inflows over the past eight days, with a peak single-day net inflow of 1.361 billion yuan, totaling 1.647 billion yuan in net inflows, averaging 206 million yuan daily [1] - As of April 21, the total margin balance on the Science and Technology Innovation Board reached 149.695 billion yuan, an increase of 932 million yuan from the previous day [1] - Notably, 38 stocks saw their margin balances increase by over 10 million yuan, with significant net purchases in stocks like Cambrian, Haiguang Information, and SMIC [1] Group 4 - The Huaxia Science and Technology Innovation Index ETF closely tracks the Science and Technology Innovation Index, with top-weighted stocks including industry leaders such as SMIC, Cambrian, and domestic equipment leader Zhongwei [2] - These companies represent the forefront of China's technology sector, showcasing the nation's commitment to technological innovation and self-reliance [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 226.67 CNY [3][5] Core Insights - The company has shown continuous high revenue growth, with a projected revenue of 90.7 billion CNY in 2024, representing a 45% year-on-year increase [8] - The company significantly increased its R&D investment to approximately 2.45 billion CNY in 2024, a 94% increase compared to the previous year, driven by the rising demand for new equipment [8] - The company's contract liabilities surged by 235% to approximately 2.59 billion CNY by the end of 2024, indicating strong order expectations [8] Financial Performance Summary - Revenue projections for 2025-2027 are 120.49 billion CNY, 156.24 billion CNY, and 200.09 billion CNY, with year-on-year growth rates of 33%, 30%, and 28% respectively [4][9] - The net profit attributable to the parent company is forecasted to be 24.33 billion CNY, 33.60 billion CNY, and 44.60 billion CNY for 2025-2027, with growth rates of 51%, 38%, and 33% respectively [3][9] - The gross margin is expected to stabilize around 42.3% to 44.3% over the forecast period, with a slight dip to 41.1% in 2024 due to structural changes in customer base [4][8] Equipment Sales and Market Position - The company experienced significant growth in etching equipment sales, with over 1,200 reaction chambers shipped in 2024, marking a historical high [8] - The company’s new deposition equipment has started contributing to revenue, with over 150 LPCVD reaction chambers shipped and approximately 476 million CNY in bulk orders received in 2024 [8]

从中证交银理财长三角指数持仓样本的行业来看，信息技术占比28.21%、金融占比19.68%、工业占比 17.49%、医药卫生占比12.68%、原材料占比10.98%、可选消费占比7.97%、通信服务占比1.79%、能源 占比0.76%、房地产占比0.44%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。每次调整的样本比例一般不超过20%。权重因子随样本定期调整而调整，调整时间与指数样本 定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不变。特殊情况下将对指数进行临 时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 据了解，中证交银理财长三角指数以长三角地区沪深市场证券为待选样本，在战略新兴企业中，选取市 值较大、收入较高、研发投入较强的40只代表性上市公司证券；在非战略新兴企业中，选取盈利能力较 强、估值较低、分红较高的60只代表性上市公司证券，共同作为指数样本，以反映沪深市场长三角地区 代表性上市公司证券的整体表现。该指数以2012年12月31日为基日，以1000.0点为基点 ...